Summary

Inactivated Vaccines Market – Scope of Report
TMR’s report on the global inactivated vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global inactivated vaccines market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global inactivated vaccines market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the inactivated vaccines market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global inactivated vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global inactivated vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global inactivated vaccines market.

The report delves into the competitive landscape of the global inactivated vaccines market. Key players operating in the global inactivated vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global inactivated vaccines market profiled in this report.

Key Questions Answered in Global inactivated vaccines Market Report
• What is the sales/revenue generated by inactivated vaccines across all regions during the forecast period?
• What are the opportunities in the global inactivated vaccines market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Inactivated Vaccines Market – Research Objectives and Research Approach
The comprehensive report on the global inactivated vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global inactivated vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global inactivated vaccines market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Inactivated Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Inactivated Vaccines Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Inactivated Vaccines Market Analysis and Forecast, by Vaccine Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine Type, 2020-2034
6.3.1. Viral Vaccine
6.3.2. Bacterial Vaccine
6.4. Market Attractiveness, by Vaccine Type
7. Global Inactivated Vaccines Market Analysis and Forecast, by Method of Inactivation
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Method of Inactivation, 2020-2034
7.3.1. Solvent Detergent Method
7.3.2. Radiation Method
7.3.3. pH Concentration
7.3.4. Others (Heat Inactivation, etc.)
7.4. Market Attractiveness, by Method of Inactivation
8. Global Inactivated Vaccines Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Subcutaneous
8.3.3. Intravenous
8.4. Market Attractiveness, by Route of Administration
9. Global Inactivated Vaccines Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Homecare Settings
9.3.4. Others (Research Centers, etc.)
9.4. Market Attractiveness, by End-user
10. Global Inactivated Vaccines Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Inactivated Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Vaccine Type, 2020-2034
11.2.1. Viral Vaccine
11.2.2. Bacterial Vaccine
11.3. Market Attractiveness, by Vaccine Type
11.4. Market Value Forecast, by Method of Inactivation, 2020-2034
11.4.1. Solvent Detergent Method
11.4.2. Radiation Method
11.4.3. pH Concentration
11.4.4. Others (Heat Inactivation, etc.)
11.5. Market Attractiveness, by Method of Inactivation
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Oral
11.6.2. Subcutaneous
11.6.3. Intravenous
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Homecare Settings
11.8.4. Others (Research Centers, etc.)
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Vaccine Type
11.11.2. By Method of Inactivation
11.11.3. By Route of Administration
11.11.4. By End-user
11.11.5. By Country
12. Europe Inactivated Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vaccine Type, 2020-2034
12.2.1. Viral Vaccine
12.2.2. Bacterial Vaccine
12.3. Market Attractiveness, by Vaccine Type
12.4. Market Value Forecast, by Method of Inactivation, 2020-2034
12.4.1. Solvent Detergent Method
12.4.2. Radiation Method
12.4.3. pH Concentration
12.4.4. Others (Heat Inactivation, etc.)
12.5. Market Attractiveness, by Method of Inactivation
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Oral
12.6.2. Subcutaneous
12.6.3. Intravenous
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Homecare Settings
12.8.4. Others (Research Centers, etc.)
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Vaccine Type
12.11.2. By Method of Inactivation
12.11.3. By Route of Administration
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Inactivated Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vaccine Type, 2020-2034
13.2.1. Viral Vaccine
13.2.2. Bacterial Vaccine
13.3. Market Attractiveness, by Vaccine Type
13.4. Market Value Forecast, by Method of Inactivation, 2020-2034
13.4.1. Solvent Detergent Method
13.4.2. Radiation Method
13.4.3. pH Concentration
13.4.4. Others (Heat Inactivation, etc.)
13.5. Market Attractiveness, by Method of Inactivation
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Oral
13.6.2. Subcutaneous
13.6.3. Intravenous
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Homecare Settings
13.8.4. Others (Research Centers, etc.)
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Vaccine Type
13.11.2. By Method of Inactivation
13.11.3. By Route of Administration
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Inactivated Vaccines Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vaccine Type, 2020-2034
14.2.1. Viral Vaccine
14.2.2. Bacterial Vaccine
14.3. Market Attractiveness, by Vaccine Type
14.4. Market Value Forecast, by Method of Inactivation, 2020-2034
14.4.1. Solvent Detergent Method
14.4.2. Radiation Method
14.4.3. pH Concentration
14.4.4. Others (Heat Inactivation, etc.)
14.5. Market Attractiveness, by Method of Inactivation
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Oral
14.6.2. Subcutaneous
14.6.3. Intravenous
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Homecare Settings
14.8.4. Others (Research Centers, etc.)
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Vaccine Type
14.11.2. By Method of Inactivation
14.11.3. By Route of Administration
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Inactivated Vaccines Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Vaccine Type, 2020-2034
15.2.1. Viral Vaccine
15.2.2. Bacterial Vaccine
15.3. Market Attractiveness, by Vaccine Type
15.4. Market Value Forecast, by Method of Inactivation, 2020-2034
15.4.1. Solvent Detergent Method
15.4.2. Radiation Method
15.4.3. pH Concentration
15.4.4. Others (Heat Inactivation, etc.)
15.5. Market Attractiveness, by Method of Inactivation
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Oral
15.6.2. Subcutaneous
15.6.3. Intravenous
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Homecare Settings
15.8.4. Others (Research Centers, etc.)
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Vaccine Type
15.11.2. By Method of Inactivation
15.11.3. By Route of Administration
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. GSK plc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Novartis AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Mylan N.V.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Sanofi S.A.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Boehringer Ingelheim International GmbH
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Merck & Co., Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. F. Hoffmann-La Roche AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Bristol-Myers Squibb Company
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Bharat Biotech
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Serum Institute of India
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. INOVIO Pharmaceuticals, Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview